Literature DB >> 2912532

Muscle cramps in cancer patients.

I Steiner1, T Siegal.   

Abstract

We prospectively evaluated 50 cancer patients with new complaints of muscle cramps. Neurologic examination and laboratory evaluation identified disorders related to neural, muscular, or biochemical abnormalities in 41 (82%) patients. Abnormalities were confined mainly to the peripheral nervous system and included peripheral neuropathy in 22 patients, root and plexus pathology in 17 patients (six with leptomeningeal metastases), and polymyositis in two patients. Hypomagnesemia accounted for muscle cramps in only one patient. Identifiable causes of muscle cramps were related mostly either to metastatic or nonmetastatic complications of the underlying malignancy (14 patients) or to complications of its treatment (21 patients). Cramps, or rather complaints of cramps, were the presenting symptom of recognizable and previously unsuspected neurologic dysfunction in 64% (27 of 42) of the identified causes. Therefore, we conclude that muscle cramps in cancer patients may not be a benign complaint and that they usually mark the presence of an identifiable neurologic disorder. The use of simple clinical and laboratory measures is rewarding in the evaluation of these patients and leads to diagnosis in the majority of them.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912532     DOI: 10.1002/1097-0142(19890201)63:3<574::aid-cncr2820630329>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Neurological abnormalities associated with celiac disease.

Authors:  Adi Vaknin; Rami Eliakim; Zvi Ackerman; Israel Steiner
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

2.  Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking.

Authors:  M Kloke; U Bingel; S Seeber
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

3.  Paraneoplastic sensorimotor neuropathy associated with breast cancer.

Authors:  K Peterson; P A Forsyth; J B Posner
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.